vs
Aquestive Therapeutics, Inc.（AQST）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
RIVERVIEW BANCORP INC的季度营收约是Aquestive Therapeutics, Inc.的1.1倍（$14.0M vs $13.0M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -244.8%，领先254.6%），RIVERVIEW BANCORP INC同比增速更快（10.4% vs 9.7%），RIVERVIEW BANCORP INC自由现金流更多（$-736.0K vs $-8.6M），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs 3.9%）
Aquestive Therapeutics是一家特种制药企业，专注于中枢神经系统疾病创新疗法的开发与商业化。公司依托专有的药物递送技术打造便于患者使用的治疗方案，服务北美、欧洲市场的医疗机构与患者，核心管线覆盖神经学与精神病学领域的未满足医疗需求。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
AQST vs RVSB — 直观对比
营收规模更大
RVSB
是对方的1.1倍
$13.0M
营收增速更快
RVSB
高出0.7%
9.7%
净利率更高
RVSB
高出254.6%
-244.8%
自由现金流更多
RVSB
多$7.8M
$-8.6M
两年增速更快
RVSB
近两年复合增速
3.9%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $13.0M | $14.0M |
| 净利润 | $-31.9M | $1.4M |
| 毛利率 | 55.2% | — |
| 营业利润率 | -221.6% | 12.4% |
| 净利率 | -244.8% | 9.8% |
| 营收同比 | 9.7% | 10.4% |
| 净利润同比 | -86.8% | 11.8% |
| 每股收益（稀释后） | $-0.26 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AQSTRVSB
| Q4 25 | $13.0M | $14.0M | ||
| Q3 25 | $12.8M | $13.6M | ||
| Q2 25 | $10.0M | $13.3M | ||
| Q1 25 | $8.7M | $12.9M | ||
| Q4 24 | $11.9M | $12.7M | ||
| Q3 24 | $13.5M | $12.8M | ||
| Q2 24 | $20.1M | $12.2M | ||
| Q1 24 | $12.1M | $9.0M |
净利润AQSTRVSB
| Q4 25 | $-31.9M | $1.4M | ||
| Q3 25 | $-15.4M | $1.1M | ||
| Q2 25 | $-13.5M | $1.2M | ||
| Q1 25 | $-22.9M | $1.1M | ||
| Q4 24 | $-17.1M | $1.2M | ||
| Q3 24 | $-11.5M | $1.6M | ||
| Q2 24 | $-2.7M | $966.0K | ||
| Q1 24 | $-12.8M | $-3.0M |
毛利率AQSTRVSB
| Q4 25 | 55.2% | — | ||
| Q3 25 | 64.8% | — | ||
| Q2 25 | 54.4% | — | ||
| Q1 25 | 58.1% | — | ||
| Q4 24 | 61.9% | — | ||
| Q3 24 | 67.2% | — | ||
| Q2 24 | 77.5% | — | ||
| Q1 24 | 63.6% | — |
营业利润率AQSTRVSB
| Q4 25 | -221.6% | 12.4% | ||
| Q3 25 | -89.6% | 10.2% | ||
| Q2 25 | -113.6% | 11.7% | ||
| Q1 25 | -222.1% | 11.3% | ||
| Q4 24 | -114.4% | 12.4% | ||
| Q3 24 | -61.2% | 15.5% | ||
| Q2 24 | 0.3% | 10.0% | ||
| Q1 24 | -74.3% | -47.5% |
净利率AQSTRVSB
| Q4 25 | -244.8% | 9.8% | ||
| Q3 25 | -120.6% | 8.1% | ||
| Q2 25 | -135.4% | 9.2% | ||
| Q1 25 | -263.0% | 8.9% | ||
| Q4 24 | -143.7% | 9.7% | ||
| Q3 24 | -85.0% | 12.2% | ||
| Q2 24 | -13.7% | 7.9% | ||
| Q1 24 | -106.4% | -34.7% |
每股收益（稀释后）AQSTRVSB
| Q4 25 | $-0.26 | $0.07 | ||
| Q3 25 | $-0.14 | $0.05 | ||
| Q2 25 | $-0.14 | $0.06 | ||
| Q1 25 | $-0.24 | $0.05 | ||
| Q4 24 | $-0.18 | $0.06 | ||
| Q3 24 | $-0.13 | $0.07 | ||
| Q2 24 | $-0.03 | $0.05 | ||
| Q1 24 | $-0.17 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $28.6M |
| 总债务越低越好 | $27.5M | — |
| 股东权益账面价值 | $-33.7M | $164.2M |
| 总资产 | $160.4M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AQSTRVSB
| Q4 25 | — | $28.6M | ||
| Q3 25 | $129.1M | $32.8M | ||
| Q2 25 | $60.5M | $34.2M | ||
| Q1 25 | $68.7M | $29.4M | ||
| Q4 24 | $71.5M | $25.3M | ||
| Q3 24 | $77.9M | $31.0M | ||
| Q2 24 | $89.9M | $27.8M | ||
| Q1 24 | $95.2M | $23.6M |
总债务AQSTRVSB
| Q4 25 | $27.5M | — | ||
| Q3 25 | $45.0M | — | ||
| Q2 25 | $45.0M | — | ||
| Q1 25 | $45.0M | — | ||
| Q4 24 | $32.5M | — | ||
| Q3 24 | $45.0M | — | ||
| Q2 24 | $45.0M | — | ||
| Q1 24 | $45.0M | — |
股东权益AQSTRVSB
| Q4 25 | $-33.7M | $164.2M | ||
| Q3 25 | $-4.1M | $163.5M | ||
| Q2 25 | $-72.6M | $162.0M | ||
| Q1 25 | $-60.9M | $160.0M | ||
| Q4 24 | $-60.2M | $158.3M | ||
| Q3 24 | $-45.4M | $160.8M | ||
| Q2 24 | $-35.5M | $155.9M | ||
| Q1 24 | $-36.3M | $155.6M |
总资产AQSTRVSB
| Q4 25 | $160.4M | $1.5B | ||
| Q3 25 | $163.6M | $1.5B | ||
| Q2 25 | $93.7M | $1.5B | ||
| Q1 25 | $102.2M | $1.5B | ||
| Q4 24 | $101.4M | $1.5B | ||
| Q3 24 | $110.0M | $1.5B | ||
| Q2 24 | $117.6M | $1.5B | ||
| Q1 24 | $129.5M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.5M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $-8.6M | $-736.0K |
| 自由现金流率自由现金流/营收 | -65.7% | -5.2% |
| 资本支出强度资本支出/营收 | 0.7% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | $-53.0M | $20.4M |
8季度趋势，按日历期对齐
经营现金流AQSTRVSB
| Q4 25 | $-8.5M | $-506.0K | ||
| Q3 25 | $-12.6M | $16.8M | ||
| Q2 25 | $-7.9M | $-697.0K | ||
| Q1 25 | $-23.4M | $8.3M | ||
| Q4 24 | $-6.5M | $2.2M | ||
| Q3 24 | $-11.9M | $764.0K | ||
| Q2 24 | $-7.0M | $5.4M | ||
| Q1 24 | $-10.4M | $12.8M |
自由现金流AQSTRVSB
| Q4 25 | $-8.6M | $-736.0K | ||
| Q3 25 | $-12.9M | $16.4M | ||
| Q2 25 | $-8.0M | $-773.0K | ||
| Q1 25 | $-23.5M | $5.6M | ||
| Q4 24 | $-6.5M | $1.9M | ||
| Q3 24 | $-12.0M | $-1.4M | ||
| Q2 24 | $-7.0M | $5.3M | ||
| Q1 24 | $-10.4M | $7.1M |
自由现金流率AQSTRVSB
| Q4 25 | -65.7% | -5.2% | ||
| Q3 25 | -100.6% | 120.1% | ||
| Q2 25 | -80.2% | -5.8% | ||
| Q1 25 | -269.9% | 43.1% | ||
| Q4 24 | -54.8% | 15.0% | ||
| Q3 24 | -88.3% | -11.3% | ||
| Q2 24 | -35.0% | 43.7% | ||
| Q1 24 | -86.4% | 79.0% |
资本支出强度AQSTRVSB
| Q4 25 | 0.7% | 1.6% | ||
| Q3 25 | 1.8% | 2.9% | ||
| Q2 25 | 1.1% | 0.6% | ||
| Q1 25 | 1.5% | 21.0% | ||
| Q4 24 | 0.1% | 2.4% | ||
| Q3 24 | 0.6% | 17.3% | ||
| Q2 24 | 0.2% | 0.9% | ||
| Q1 24 | 0.2% | 62.0% |
现金转化率AQSTRVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
